Question 1

What are the potential side effects of the drugs being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) clinical trial (NCT06589440). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) clinical trial (NCT06589440). Contact the study team or your healthcare provider for specific answers.

Question 3

What will my participation involve in terms of visits and tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) clinical trial (NCT06589440). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any risks associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) clinical trial (NCT06589440). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) clinical trial (NCT06589440). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) clinical trial (NCT06589440). Contact the study team or your healthcare provider for specific answers.

What this study is about